Goukon Y, Sasano H, Nishihira T, Nagura H, Mori S
Second Department of Surgery, Tohoku University School of Medicine, Sendai, Japan.
Anticancer Res. 1994 May-Jun;14(3B):1305-12.
Abnormalities of p53, a known tumor suppressor gene, has been detected in various human malignant neoplasms. In this study, we analyzed immunohistochemically the localization of p53 using three different antibodies, PAb1801, DO-7, and CM-1 in 49 patients with esophageal squamous cell carcinoma. We compared the expression of p53 with the clinicopathological features, proliferating cell nuclear antigen (PCNA), and DNA ploidy. In addition, we performed flow cytometric analysis of p53 using DO-7 in 33 cases in order to evaluate the correlation between p53 overexpression and DNA ploidy simultaneously. By immunohistochemistry, immunoreactive p53 was observed in the nuclei of carcinoma cells in 29 cases (59%). Relatively larger diameter tumors (more than 5cm), poorly differentiated tumors, tumors with distant lymph node metastasis, and DNA aneuploidy tumors were positive for p53 more frequently. p53-positive cases had a higher PCNA labeling index and a poorer prognosis than p53-negative cases. By two parameter flow cytometric analysis, p53 was detected in 16 cases (49%) and DNA aneuploidy was detected in 27 cases (82%). A higher p53-positive rate (15/27.56%) was observed in DNA aneuploidy cases than in DNA diploidy cases (1/6.17%). However, this difference was not statistically significant. The p53 results by immunohistochemistry and flow cytometry were the same in 25 out of 33 cases (76%). These results suggest the possible correlation between p53 abnormalities and DNA aneuploidy and that analysis of p53 protein is useful for prediction of clinical course in esophageal squamous cell carcinoma.
已知的肿瘤抑制基因p53的异常已在多种人类恶性肿瘤中被检测到。在本研究中，我们使用三种不同的抗体PAb1801、DO-7和CM-1，对49例食管鳞状细胞癌患者进行了p53定位的免疫组织化学分析。我们将p53的表达与临床病理特征、增殖细胞核抗原（PCNA）和DNA倍体进行了比较。此外，我们对33例患者使用DO-7进行了p53的流式细胞术分析，以便同时评估p53过表达与DNA倍体之间的相关性。通过免疫组织化学，在29例（59%）癌细胞核中观察到免疫反应性p53。相对较大直径的肿瘤（超过5cm）、低分化肿瘤、有远处淋巴结转移的肿瘤和DNA非整倍体肿瘤p53阳性更为常见。p53阳性病例的PCNA标记指数较高，预后比p53阴性病例差。通过双参数流式细胞术分析，在16例（49%）中检测到p53，在27例（82%）中检测到DNA非整倍体。DNA非整倍体病例的p53阳性率（15/27，56%）高于DNA二倍体病例（1/6，17%）。然而，这种差异无统计学意义。33例中有25例（76%）免疫组织化学和流式细胞术检测的p53结果相同。这些结果提示p53异常与DNA非整倍体之间可能存在相关性，并且p53蛋白分析有助于预测食管鳞状细胞癌的临床病程。
